IDEV Technologies Enters Into an Exclusive Distribution Agreement With TriReme Medical

Company Expands Product Portfolio

WEBSTER, Texas, June 24, 2010 - IDEV Technologies, Incorporated (IDEV), an emerging leader in the
development and marketing of minimally invasive medical technologies, today
announced that it has entered into an exclusive distribution agreement
covering the U.S. and Germany for TriReme Medical, Inc.'s (TriReme)
GliderXtreme(TM) PTA balloon catheter, an advanced product with specific
features for the expanding Peripheral Arterial Disease (PAD) market. The PAD
market represents more than a US$2.5 billion device revenue opportunity in
the U.S., growing at nearly 10 percent annually with significant
opportunities for next generation stents and balloon catheters. IDEV expects
to launch the GliderXtreme in the third quarter of 2010.

TriReme recently received clearance from the U.S. Food and Drug
Administration (FDA) for the GliderXtreme catheter, a highly differentiated
advanced balloon catheter system with an expanded matrix of sizes including
longer balloon lengths, an atraumatic tapered tip and shaft construction
reinforced for torque transmission and exceptional pushability. GliderXtreme
is designed to cross difficult and highly diseased lesions to restore blood
flow in complex anatomy.

"IDEV is building a strong global foundation, which makes it an ideal
partner for us," Dr. Eitan Konstantino, President and CEO of TriReme said.
"IDEV's proven commercial capabilities are undeniable. In addition, both
companies are engaged in the development of future tools for the PAD market,
IDEV with its durable, flexible, and easy-to-use SUPERA(R) stent and TriReme
with the GliderXtreme, a next generation balloon catheter technology designed
to cross a broad range of lesions. We look forward to working with IDEV to
drive market adoption."

IDEV's self-expanding SUPERA interwoven nitinol stent is a novel stent
platform designed for the treatment of biliary and peripheral artery
diseases. The SUPERA stent has received CE Mark approval in Europe for
biliary and peripheral vascular indications and is currently the focus of a
prospective, FDA-IDE approved, single-arm clinical trial in 258 patients at
up to 40 sites in the U.S. The company is also focused on developing and
adding highly differentiated products to its portfolio.

Christopher M. Owens, President and CEO of IDEV, commented that, "IDEV
and TriReme are both creating advanced, innovative products to fill
significant unmet needs in rapidly expanding medical device markets. We are
very impressed with TriReme's catheter products and development capabilities.
Given the promising results and growth opportunities we are experiencing with
our SUPERA stent, adding a complementary and technologically advanced product
offering makes sense both strategically and clinically. We look forward to
working closely with TriReme."

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of
next generation medical devices for use in the interventional radiology,
vascular surgery and cardiology marketplace. IDEV's worldwide headquarters is
located in Webster, Texas and its European headquarters is located in
Beuningen, Netherlands.

About TriReme Medical, Inc.

Based in Pleasanton, CA, TriReme Medical, Inc., is a privately held
medical device company dedicated to the development, manufacturing, and
commercialization of advanced therapeutic solutions for the treatment of
complex vascular disease. TriReme's headquarter is located in Pleasanton,
California.

    Contact: Julie Nguyen, Marketing Communications Manager
             IDEV Technologies, Incorporated
             +1-281-525-2000

Julie Nguyen, Marketing Communications Manager of IDEV Technologies, Incorporated, +1-281-525-2000